Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions 
Starmer’s China Visit Highlights Western Balancing Act Amid U.S.-China Rivalry 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Gold Prices Pull Back After Record Highs as January Rally Remains Strong 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
UK Employers Plan Moderate Pay Rises as Inflation Pressures Ease but Persist 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
China Factory Activity Slips in January as Weak Demand Weighs on Growth Outlook 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Asian Markets Slide as Silver Volatility, Earnings Season, and Central Bank Meetings Rattle Investors 
Why Trump’s new pick for Fed chair hit gold and silver markets – for good reasons 
Gold Prices Stabilize in Asian Trade After Sharp Weekly Losses Amid Fed Uncertainty 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
JW Pharmaceutical will use the zebrafish to develop new drugs and expand indications of its drug candidates.
To expedite the process, the South Korean drug developer has inked a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models.
Zefit will provide disease-specific zebrafish models using gene editing technology and a drug screening platform.
Zebrafish, a tropical fish species whose genetic structure is more than 80 percent similar to humans, is increasingly being used as a non-clinical intermediary research model.
Zebrafish can replace mammalian experiments, according to Zefit.
Conducting experiments with zebrafish can bring down costs to about one-tenth of those for mammals.
JW Pharmaceutica plans to use zebrafish to bridge the gap between non-clinical and clinical research.
Zebrafish experiments can be 91 percent similar to those conducted with mammals.
According to Shin Jun-nyeong, CEO of Zefit, Interest in zebrafish is increasing among regulatory agencies such as the US Food and Drug Administration (FDA).
